Health Canada Approves Updated Protocol for Redsenol-1 Plus Cancer Fatigue Study

What Happened

Health Canada has cleared a revised clinical trial protocol for Redsenol-1 Plus, a botanical supplement currently under investigation for managing cancer-related fatigue. The regulatory body confirmed it has no objections to the updated research framework submitted by Canada Royal Enoch Phytomedicine Ltd.

The study, which began in 2022, evaluates the efficacy of rare ginsenoside capsules in patients undergoing treatments like chemotherapy and radiotherapy. Researchers adjusted the protocol based on ongoing operational data to improve participant access and refine the study design.

This update allows the research team to continue gathering longitudinal data on the supplement. The product is already listed in the U.S. National Cancer Institute’s Drug Dictionary, marking it as a subject of active scientific interest regarding its biological effects.

The Core Points

Health Canada approved a protocol amendment for the Redsenol-1 Plus clinical trial.
The study focuses on treating cancer-related fatigue in patients undergoing active therapies.
The supplement consists of sixteen rare ginsenosides derived from ginseng.
The trial, active since 2022, is registered on ClinicalTrials.gov under identifier NCT05664009.
Protocol adjustments were made to improve participant access and refine data collection.

Context in 60 Seconds

Cancer-related fatigue remains a pervasive issue for patients undergoing intensive medical treatments, often significantly impacting their quality of life long after therapy concludes. Despite its prevalence, effective interventions remain limited, driving ongoing research into natural health products that may offer supportive care.

The biotechnology sector is increasingly focusing on identifying botanical compounds with specific biological activities that can be integrated into traditional oncology treatment plans. By standardizing these formulations, researchers aim to provide evidence-based options for patients struggling with the long-term side effects of conventional cancer care.

Bottom Line

Health Canada's approval allows for the continuation of a clinical trial investigating whether a specific ginsenoside supplement can effectively mitigate exhaustion in cancer patients.

Loading briefing details...